Preclinical and first-in-human phase I studies of KW-2450, an oral tyrosine kinase inhibitor with insulin-like growth factor receptor-1/insulin receptor selectivity.
Cancer Sci
; 107(4): 499-506, 2016 Apr.
Article
in En
| MEDLINE
| ID: mdl-26850678
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Breast Neoplasms
/
Receptor, Insulin
/
Receptor, IGF Type 1
/
Colonic Neoplasms
/
Receptor, ErbB-2
/
Protein Kinase Inhibitors
Type of study:
Prognostic_studies
Limits:
Adult
/
Aged
/
Animals
/
Female
/
Humans
Language:
En
Journal:
Cancer Sci
Year:
2016
Document type:
Article
Affiliation country: